Evidence map›Paper›PMID 24316825›Full record

ArticleActa crystallographica. Section F, Structural biology and crystallization communications2013

Two high-resolution structures of the human E3 ubiquitin ligase Siah1.

Vadim Rimsa, Thomas C Eadsforth, William N Hunter

Open access · hybridAbstract read
In one paragraph

Article in Acta crystallographica. Section F, Structural biology and crystallization communications, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Vadim RimsaDivision of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dundee DD1 5EH, Scotland.
Thomas C Eadsforth
William N Hunter
University of Dundee · GB

Funding

Biotechnology and Biological Sciences Research CouncilWellcome TrustWellcome Trust 082596Wellcome Trust 094090Wellcome Trust 100476
6 · The paper itself

Abstract

Siah1 is an E3 ubiquitin ligase that contributes to proteasome-mediated degradation of multiple targets in key cellular processes and which shows promise as a therapeutic target in oncology. Structures of a truncated Siah1 bound to peptide-based inhibitors have been reported. Here, new crystallization conditions have allowed the determination of a construct encompassing dual zinc-finger subdomains and substrate-binding domains at significantly higher resolution. Although the crystals appear isomorphous, two structures present distinct states in which the spatial orientation of one zinc-finger subdomain differs with respect to the rest of the dimeric protein. Such a difference, which is indicative of conformational freedom, infers potential biological relevance related to recognition of binding partners. The crystallization conditions and improved models of Siah1 may aid future studies investigating Siah1-ligand complexes.

Indexed as

Models, MolecularAmino Acid SequenceCrystallography, X-RayHumansMolecular Sequence DataNuclear ProteinsProteasome Endopeptidase ComplexProtein Interaction Domains and MotifsProtein MultimerizationProtein Structure, SecondaryRecombinant ProteinsSeven in Absentia ProteinsStructural Homology, ProteinUbiquitin-Protein LigasesNuclear ProteinsProteasome Endopeptidase ComplexRecombinant ProteinsSeven in Absentia ProteinsUbiquitin-Protein LigasesE3 ubiquitin ligaseseven-in-absentia homologue 1 (Siah1)zinc finger

Identifiers

PMID24316825
PMCPMC3855715
OpenAlexW2124079757

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.